MedTrace Logo

First-in-Human Study of Orally Administered GS-441524 for COVID-19

NCT04859244 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-08-10

No results posted yet for this study

Summary

This is a two-part study is to evaluate the multi-day safety, tolerability, and pharmacokinetics (PK) of orally administered GS-441524 in a healthy human volunteer.

Conditions

Interventions

DRUG

GS-441524

750 mg administered as a solution

Sponsors & Collaborators

  • Copycat Sciences LLC

    lead INDUSTRY

Principal Investigators

  • Victoria Yan · Copycat Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-05-01
Completion
2021-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04859244 on ClinicalTrials.gov